These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1374 related articles for article (PubMed ID: 31135299)

  • 1. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC.
    Chen SL; Xiao H; Xie ZL; Shen JX; Chen ZB; Wang YQ; Li B; Peng ZW; Kuang M; Lai JM; Peng S
    Eur Radiol; 2020 Jun; 30(6):3473-3485. PubMed ID: 32048035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
    Fan W; Zhu B; Chen S; Wu Y; Zhao X; Qiao L; Huang Z; Tang R; Chen J; Lau WY; Chen M; Li J; Kuang M; Peng Z
    JAMA Oncol; 2024 Aug; 10(8):1047-1054. PubMed ID: 38900435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
    Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.
    Chen ZH; Zhang XP; Zhou TF; Wang K; Wang H; Chai ZT; Shi J; Guo WX; Cheng SQ
    Eur J Surg Oncol; 2019 Nov; 45(11):2188-2196. PubMed ID: 31256949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    J Dig Dis; 2020 May; 21(5):287-292. PubMed ID: 32315498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
    Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Kariya S; Yoshii K; Sekimoto M
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1217-1224. PubMed ID: 33906315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.
    Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W
    Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.
    Ye Z; Deng Z; Jiang S; Wang T; Liu L; Jiang K; Zhang Y
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1394-1402. PubMed ID: 33948697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
    Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.